- Oral presentation
- Open Access
Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)
© Rockstroh et al; licensee BioMed Central Ltd. 2010
- Published: 8 November 2010
- Virologic Failure
- Antiviral Response
- Integrase Inhibitor
- Pharmacokinetic Variability
S/GSK1349572, a next-generation HIV-1 integrase inhibitor, has previously demonstrated potent antiviral activity in Phase 2a with once-daily, unboosted dosing. SPRING-1 is an ongoing dose-ranging study designed to select a dose to for Phase 3 evaluation.
SPRING-1 is a Phase 2b, multicentre, partially-blinded study in therapy-naïve adults, randomized 1:1:1:1 to 10mg, 25mg or 50mg of S/GSK1349572 or efavirenz(EFV) 600mg once-daily with either co-formulated TDF/FTC or ABC/3TC.
Planned Week 24 Interim Analysis Results
S/GSK1349572 10 mg (n=53)
S/GSK1349572 25mg (n=51)
S/GSK1349572 50mg (n=51)
EFV control (n=50)
Mean baseline HIV-1 RNA (log10 c/mL)
%<50c/mL at 24 wks (by TLOVR)
Median baseline (change from baseline at 24 weeks) CD4+ cells/mm3
S/GSK1349572 administered once-daily without a PK booster was well tolerated with potent antiviral activity at all doses explored in SPRING-1. The greater CD4+ cell increases on S/GSK1349572 merit further observation and confirmation.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.